1. Academic Validation
  2. USP5 deubiquitylates and stabilizes FcεRIγ to enhance IgE-induced mast cell activation and allergic inflammation

USP5 deubiquitylates and stabilizes FcεRIγ to enhance IgE-induced mast cell activation and allergic inflammation

  • Sci Signal. 2025 Jul 29;18(897):eadr3411. doi: 10.1126/scisignal.adr3411.
Zi-Wen Zhou 1 Xue-Ting Xu 1 Qiu-Ni Liang 2 Yan-Mei Zhou 1 Wan-Zhen Hu 3 Shan Liu 1 Yu-Xin Jiao 1 Shu-Chen Zhang 4 Kunmei Ji 1 Jia-Jie Chen 1
Affiliations

Affiliations

  • 1 Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
  • 2 First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
  • 3 Shenzhen University General Hospital, Shenzhen, China.
  • 4 Department of Allergy, Zhongnan Hospital, Wuhan University, Wuhan, China.
Abstract

Antigen-mediated aggregation of immunoglobulin E (IgE) bound to the high-affinity IgE receptor (FcεRI) initiates mast cell activation and allergic inflammation. Here, we investigated the role of Ubiquitin-Specific Protease 5 (USP5) in IgE-mediated mast cell activation and its regulation of FcεRIγ stability. We found that USP5 knockdown inhibited the IgE-induced release of β-hexosaminidase and histamine from mast cells and attenuated allergic inflammation in mice. USP5 interacted with FcεRIγ in mast cells, leading to its deubiquitylation and stabilization. In addition, USP5 reversed the K48-linked polyubiquitylation of FcεRIγ. USP5 knockdown in mast cells or HEK293T cells increased the binding of the E3 ubiquitin Ligase Cbl-b to FcεRIγ, leading to an increase in FcεRIγ polyubiquitylation and degradation. The USP5 inhibitor WP1130 attenuated IgE-mediated mast cell activation and allergic inflammation in mice. Together, these findings describe the molecular mechanism of USP5-mediated regulation of FcεRIγ stability in mast cells and identify the USP5-FcεRIγ axis as a potential drug target for the therapy of IgE/FcεRI-mediated allergic diseases.

Figures
Products
Inhibitors & Agonists